Aldeyra Therapeu (ALDX) Stock Price, Quote & News

Company Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator th...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 761 4904

Fax: 339 674 6495

Website: www.aldeyra.com

Address:

131 Hartwell Avenue, Suite 320, Lexington, United States

Sunnie3 Feb. 3 at 4:30 PM

$ALDX https://finance.yahoo.com/news/wall-street-analysts-predict-65-145502358.html

0 · Reply

PeterV9764 Feb. 3 at 1:16 PM

$ALDX Good morning Everyone: From what I’m hearing the JP conference went very well with new investors. The Hawaiian eye Conference was also very successful with Abbvie more positive than ever …. Im looking for full label and press release on or before the 16th from the company ! Fingers crossed 🤞 Peter

5 · Reply

Stanley92 Feb. 2 at 9:27 PM

$ALDX I still have faith in this. Good news before 16/02.

1 · Reply

Bigbas Feb. 2 at 2:13 PM

$ALDX we gonna spike up like the other day and drop back or is the start of the pre PDUFA climb?

1 · Reply

Smellmahass Jan. 31 at 2:13 AM

$TVTX This and $ALDX these two looks like approval probability is better right?

1 · Reply

Moneymachineuser Jan. 30 at 7:41 PM

$ALDX Todd has been buying and selling, good job pal

0 · Reply

Moneymachineuser Jan. 30 at 7:41 PM

$ALDX come-on someone re share my 4.1 comment like y'all did with the capr one even tho I was calling th dump to $3.X and then it bounced LLL

1 · Reply

AllinDeyra Jan. 30 at 5:31 PM

$ALDX 5,93 usd high today

1 · Reply

AllinDeyra Jan. 30 at 5:30 PM

$ALDX crazy movement to 5,9 usd...Direction is great even we are back now at 5,35 for the moment

0 · Reply

MJPTrades Jan. 30 at 3:14 PM

$ALDX 😪 shooting star

0 · Reply

Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst

Dec 16, 2025, 10:09 AM EST - 7 weeks ago

Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript

Dec 15, 2025, 7:30 PM EST - 7 weeks ago

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Nov 13, 2025, 3:11 PM EST - 2 months ago

Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript

Nov 13, 2025, 7:00 AM EST - 2 months ago

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Nov 11, 2025, 7:01 AM EST - 3 months ago

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:00 AM EST - 3 months ago

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

Oct 28, 2025, 7:01 AM EDT - 3 months ago

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Oct 10, 2025, 4:32 AM EDT - 4 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALEC BDTX CHRS

Sep 3, 2025, 7:01 AM EDT - 5 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:01 AM EDT - 5 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aug 19, 2025, 7:01 AM EDT - 6 months ago

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aug 6, 2025, 7:01 AM EDT - 6 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 24, 2025, 7:00 AM EDT - 6 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Jul 17, 2025, 7:00 AM EDT - 7 months ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jul 2, 2025, 9:23 PM EDT - 7 months ago

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

Jun 26, 2025, 7:00 AM EDT - 7 months ago

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Jun 17, 2025, 7:00 AM EDT - 8 months ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

May 29, 2025, 7:01 AM EDT - 8 months ago

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 7, 2025, 4:07 PM EDT - 9 months ago

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law

May 7, 2025, 8:46 AM EDT - 9 months ago

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

May 6, 2025, 4:42 PM EDT - 9 months ago

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman

May 6, 2025, 3:48 PM EDT - 9 months ago

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss

May 5, 2025, 6:34 PM EDT - 9 months ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 5, 2025, 4:00 PM EDT - 9 months ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 5, 2025, 3:38 PM EDT - 9 months ago

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation

May 3, 2025, 7:18 AM EDT - 9 months ago

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

May 1, 2025, 8:08 AM EDT - 9 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company

Apr 30, 2025, 3:38 PM EDT - 9 months ago

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law

Apr 29, 2025, 4:07 PM EDT - 9 months ago

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law

Apr 29, 2025, 9:49 AM EDT - 10 months ago

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Apr 28, 2025, 9:00 PM EDT - 10 months ago

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

TTGT

Apr 28, 2025, 3:46 PM EDT - 10 months ago

ALDX NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of Pending Securities Investigation - Contact BFA Law if You Lost Money

Apr 27, 2025, 8:20 AM EDT - 10 months ago

ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law

Apr 25, 2025, 3:22 PM EDT - 10 months ago

ALDX SHAREHOLDER NEWS: Aldeyra Therapeutics, Inc. 75% Stock Plummet Leads to Securities Investigation - Investors are Urged to Contact BFA Law

Apr 25, 2025, 7:36 AM EDT - 10 months ago

ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation – Contact BFA Law if You Lost Money

Apr 24, 2025, 3:18 PM EDT - 10 months ago

ALDX NOTICE: A Securities Investigation was initiated on behalf of Aldeyra Therapeutics, Inc. Investors - Contact BFA Law

Apr 23, 2025, 3:36 PM EDT - 10 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics, Inc. is being Investigated for Securities Violations - Investors are Notified to Contact BFA Law

Apr 23, 2025, 8:18 AM EDT - 10 months ago

LEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Investors are Notified of the Pending Securities Investigation - Contact BFA Law

Apr 22, 2025, 3:23 PM EDT - 10 months ago

ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being Investigated - Contact the Firm if You Lost Money

Apr 21, 2025, 10:52 AM EDT - 10 months ago

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity

Apr 21, 2025, 8:33 AM EDT - 10 months ago

ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit Securities Violations? Contact BFA Law (NASDAQ:ALDX)

Sunnie3 Feb. 3 at 4:30 PM

$ALDX https://finance.yahoo.com/news/wall-street-analysts-predict-65-145502358.html

0 · Reply

PeterV9764 Feb. 3 at 1:16 PM

5 · Reply

Stanley92 Feb. 2 at 9:27 PM

$ALDX I still have faith in this. Good news before 16/02.

1 · Reply

Bigbas Feb. 2 at 2:13 PM

$ALDX we gonna spike up like the other day and drop back or is the start of the pre PDUFA climb?

1 · Reply

Smellmahass Jan. 31 at 2:13 AM

$TVTX This and $ALDX these two looks like approval probability is better right?

1 · Reply

Moneymachineuser Jan. 30 at 7:41 PM

$ALDX Todd has been buying and selling, good job pal

0 · Reply

Moneymachineuser Jan. 30 at 7:41 PM

$ALDX come-on someone re share my 4.1 comment like y'all did with the capr one even tho I was calling th dump to $3.X and then it bounced LLL

1 · Reply

AllinDeyra Jan. 30 at 5:31 PM

$ALDX 5,93 usd high today

1 · Reply

AllinDeyra Jan. 30 at 5:30 PM

$ALDX crazy movement to 5,9 usd...Direction is great even we are back now at 5,35 for the moment

0 · Reply

MJPTrades Jan. 30 at 3:14 PM

$ALDX 😪 shooting star

0 · Reply

MJPTrades Jan. 30 at 2:42 PM

$ALDX wtf was that lol immediate 50k share dump at market open then straight line up to 11% gain on day and then immediately back down? Price movement has been so weird recently very low volume and mostly selling only but price keeps going up

3 · Reply

Bigbas Jan. 30 at 2:31 PM

$ALDX wowzer!!

0 · Reply

Milanfinest Jan. 30 at 1:58 PM

$ALDX 4.50 area and bounce if it goes wrong? Looking for a bingo re entry for fun

1 · Reply

RigidFlexibility Jan. 30 at 1:59 AM

$ALDX ….man, quiet in here. Guess I check in too much. Gotta fund, er, find another hobby, lol. Feb almost here. Hanging out,multiplying # of sh by potential pps. Dreaming. Its only money. GLTA longs.Bully.

1 · Reply